Archives
-
HyperScript III RT SuperMix in CRC qPCR
2026-09-26
Translate colorectal cancer subtype findings into a practical RT-qPCR validation workflow with integrated genomic DNA cleanup. HyperScript III RT SuperMix supports assays across low-input and high-GC RNA, while careful controls keep exploratory biomarker measurements distinct from clinical conclusions.
-
From OVA mRNA to More Interpretable Immune Models
2026-09-25
A delivery-aware framework for using EZ Cap™ OVA mRNA to study antigen expression and immune responses—while separating transcript quality from formulation effects and inflammatory signals.
-
Cell Counting Kit-8 for SYT7 Tumor Research
2026-09-25
Use CCK-8 to quantify viable-cell responses when testing how G-quadruplex ligands affect SYT7-linked tumor growth. This practical guide connects the assay’s WST-8 chemistry to plate-based workflows, controls, and interpretation limits—without treating metabolic signal as a direct measure of gene expression.
-
ML-Guided LNPs for Microglial mRNA Immunomodulation
2026-09-24
Rafiei, Shojaei, and Chau used supervised machine learning to connect lipid nanoparticle design with mRNA transfection and microglial phenotype, screening 216 formulations across resting and activated BV-2 cells. Their strongest model supported selection of an HA-modified formulation that delivered IL-10 mRNA and reduced inflammatory readouts, with follow-up evidence in human iPSC-derived microglia; the results are promising but remain preclinical.
-
CDK9 inhibitor (A3294): Practical Lab Guide
2026-09-24
CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor for investigating CDK9-dependent transcription elongation and P-TEFb-related processes. It is suited to focused biochemical or cell-based work, including MT4 HIV-1 research, but not broad-spectrum CDK inhibition or workflows requiring long-term storage of prepared solutions.
-
Self-Amplifying RNA Improves Influenza B Vaccine Protection
2026-09-23
A mouse study compared nucleoside-modified mRNA, self-amplifying RNA (saRNA), and circular RNA vaccine approaches after optimizing influenza hemagglutinin sequences. At a reported 0.1 μg dose, trivalent saRNA produced durable antibody responses and complete protection against influenza B challenge, highlighting a platform-specific dose-sparing result that still requires validation beyond animal models.
-
SAFB, Satellite RNAs, and Heterochromatin Phase Separation
2026-09-23
Huo et al. identify SAFB and major satellite RNAs as cooperating regulators of pericentromeric heterochromatin architecture, linking RNA binding to phase-separation behavior and genome-wide structural organization. Their findings provide a mechanistic framework for understanding how nuclear matrix proteins and repeat transcripts stabilize higher-order chromatin, while also defining important limits for translating condensate observations into functional genome models.
-
L. gasseri Protects the Colonic Barrier via NR1I3
2026-09-22
Qian et al. show that Lactobacillus gasseri ATCC33323 alleviates DSS-induced colitis in mice by preserving E-cadherin-dependent epithelial barrier function. The study links probiotic activity to NR1I3-mediated regulation of CDH1 transcription and provides a mechanistic framework for investigating strain-specific interventions in intestinal inflammation.
-
Making mRNA Delivery Measurable
2026-09-22
A mechanistic and strategic guide to using ARCA Cy3 EGFP mRNA (5-moUTP) to distinguish cellular uptake, intracellular trafficking, endosomal escape, and productive translation in mammalian cell studies.
-
β-Galactosidase Reporter Assay Kit Guide
2026-09-21
The β-Galactosidase Reporter Assay Kit can turn promoter activity into a practical, quantitative readout. This guide connects β-galactosidase assay design with cross-kingdom promoter research in Escherichia coli and Saccharomyces cerevisiae.
-
Rhamnolipid-Stabilized mRNA Nanovaccines
2026-09-21
This study replaces PEG-lipids with microbial rhamnolipids to create mRNA lipid nanoparticles that combine colloidal stabilization with intrinsic immune stimulation. The resulting particles improved dendritic-cell targeting, lymph-node expression, and Th1-skewed adaptive responses while showing a more favorable repeat-dose inflammatory profile than size-matched PEG-LNPs.
-
ATS-9R Workflow for Adipose Gene Silencing
2026-09-20
ATS-9R combines Prohibitin recognition with a nona-arginine nucleic-acid delivery domain to concentrate gene modulation in white adipose tissue. This practical workflow covers complex formation, adipocyte and macrophage assays, in vivo dosing logic, and troubleshooting for obesity-associated inflammation and metabolic disease research.
-
Dibutyryl-cAMP, sodium salt: Reliable Assays
2026-09-19
Learn how Dibutyryl-cAMP, sodium salt (SKU B9001) can improve the interpretability of cAMP perturbation experiments involving viability, proliferation, cytotoxicity, and differentiation. This scenario-based guide covers mechanism, solvent compatibility, protocol controls, data interpretation, and practical supplier selection.
-
Separating Growth Inhibition from Cancer Cell Death
2026-09-18
Hannah Schwartz’s dissertation shows that relative viability and fractional viability are not interchangeable measures of anticancer drug response. By separating proliferative inhibition from cell killing and considering their timing, the work offers a clearer framework for interpreting in vitro efficacy data and designing translational experiments.
-
Biomimetic IL-12 mRNA Nanoparticles for GBM
2026-09-18
Zhao et al. developed cRGD-modified cancer-cell-membrane-coated calcium carbonate nanoparticles for ultrasound-triggered delivery of IL-12 mRNA in glioblastoma. The platform combines brain-tumor targeting, ultrasound-induced necroptosis, and local cytokine expression, offering a mechanistically integrated approach to overcoming the blood–brain barrier and reshaping the glioblastoma immune microenvironment.